Respiratory Syncytial Virus Rsv clinical trials

Explore recruiting respiratory syncytial virus rsv clinical trials.

Recruiting respiratory syncytial virus rsv studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Respiratory Syncytial Virus Rsv trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL)

Germany, Spain, Finland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)-RSV immunisation adaptive platform trial

Belgium, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications

Slovakia, Spain, Poland, Czechia, Netherlands, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (≥18 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses and compared to healthy controls (≥50 years of age) receiving 1 dose

Spain, Italy, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease

Germany, Spain, Hungary, Finland, France, Norway +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, randomized, controlled, partially blind, immuno-bridging study to evaluate immunogenicity, reactogenicity, safety and the occurrence of RSV-associated respiratory tract illness after administration of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults aged 60 years and older.

Finland, Poland, Spain

Phase III and phase IV (Integrated) EU CTIS Study details

Respiratory Syncytial Virus Rsv trials by city

Respiratory Syncytial Virus Rsv in Toronto Respiratory Syncytial Virus Rsv in Vancouver Respiratory Syncytial Virus Rsv in Montreal Respiratory Syncytial Virus Rsv in Calgary Respiratory Syncytial Virus Rsv in Edmonton Respiratory Syncytial Virus Rsv in Ottawa Respiratory Syncytial Virus Rsv in Winnipeg Respiratory Syncytial Virus Rsv in Quebec City Respiratory Syncytial Virus Rsv in Hamilton Respiratory Syncytial Virus Rsv in Kitchener Respiratory Syncytial Virus Rsv in London Respiratory Syncytial Virus Rsv in Halifax Respiratory Syncytial Virus Rsv in New York Respiratory Syncytial Virus Rsv in Los Angeles Respiratory Syncytial Virus Rsv in Chicago Respiratory Syncytial Virus Rsv in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease